Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04506684 · ClinicalTrials.gov registry record
Reveal LINQ Respiration Clinical Study
A clinical trial, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- Completed
- Registry status
- 79
- Enrollment target
NCT04506684: Completed study, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
NCT04506684 is a clinical trial that has completed, run by Medtronic Cardiac Rhythm and Heart Failure. The registered enrollment target is 79 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04506684 has completed, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- COMPLETED
- Registry status
- 79 participants
- Enrollment target
Study Summary
The LINQ™ Respiration study will collect and characterize Reveal LINQ™ derived respiration data from patients undergoing a simulated 24-hour time period while being monitored with capnography.
Primary Outcome
The primary objective is to demonstrate an acceptable agreement between Reveal LINQ™ derived respiratory rate and capnography waveform-derived respiratory rate.
Interventions
- DEVICE Investigational RAMware downloaded onto Reveal LINQ device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2020-09-25 |
| Est. Completion | 2021-07-31 |
What the finished NCT04506684 record still lists
NCT04506684 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 79 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Investigational RAMware downloaded onto Reveal LINQ device is the first listed.
NCT04506684 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04506684 about?
NCT04506684 is a clinical study titled "Reveal LINQ Respiration Clinical Study". The LINQ™ Respiration study will collect and characterize Reveal LINQ™ derived respiration data from patients undergoing a simulated 24-hour time period while being monitored with capnography.
What is the current status of trial NCT04506684?
This trial is currently completed. The enrollment target is 79 participants. The study started on 2020-09-25. Estimated completion is 2021-07-31.
What interventions are being tested in trial NCT04506684?
The interventions under investigation include: Investigational RAMware downloaded onto Reveal LINQ device (DEVICE).
Who is sponsoring clinical trial NCT04506684?
This trial is sponsored by Medtronic Cardiac Rhythm and Heart Failure, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05798897 · 79 participants · Phase 1
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- NCT06042439 · 79 participants · NA
AM vs PM Exercise Training
- NCT06223555 · 79 participants · NA
Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI